IGF2BP2 gene showed immunophenotype-dependent overexpression in acute myeloid leukemia patients

IF 0.9 Q4 GENETICS & HEREDITY

Gene Reports Pub Date : 2025-08-30 DOI:10.1016/j.genrep.2025.102331

Mustafa A. Bashi , Noor W. Ali , Dhay A. Azeez , Maryam H. Ibrahem , Mohammed K. Al-Qayyim , Ali H. Ad'hiah

{"title":"IGF2BP2 gene showed immunophenotype-dependent overexpression in acute myeloid leukemia patients","authors":"Mustafa A. Bashi , Noor W. Ali , Dhay A. Azeez , Maryam H. Ibrahem , Mohammed K. Al-Qayyim , Ali H. Ad'hiah","doi":"10.1016/j.genrep.2025.102331","DOIUrl":null,"url":null,"abstract":"<div><div>IGF2BP2 (insulin-like growth factor 2 mRNA-binding protein 2) is a gene that encodes a protein (IGF2BP2) involved in promoting RNA stability, facilitating RNA translation, and regulating post-transcriptional processes. Recent evidence indicates that IGF2BP2 is overexpressed in acute myeloid leukemia (AML). However, the association between IGF2BP2 expression and genetic abnormalities in AML remains poorly understood. Furthermore, IGF2BP2 expression across AML subtypes and immunophenotypes has yet to be characterized. In this retrospective study, IGF2BP2 mRNA expression was evaluated in 106 AML patients, with a focus on understanding the relationship between IGF2BP2 expression and disease subtype, genetic abnormalities, and peripheral blood immunophenotypes. IGF2BP2 expression (relative fold change; 2−ΔΔCt) in peripheral blood was determined using quantitative PCR analysis. Results revealed that IGF2BP2 was overexpressed in AML patients (median: 1.20; interquartile range 25–75 %: 0.73–2.39; range: 0.51–4.25). IGF2BP2 overexpression was more pronounced in cases positive for cluster of differentiation (CD) 4, CD11b, CD35, CD36, cTdT (cytoplasmic terminal deoxynucleotidyl transferase), and IREM2 (immune receptor expressed by myeloid cells 2) than in cases negative for the corresponding markers, but the adjusted probability for multiple comparisons was not statistically significant (0.14, 0.07, 0.21, 0.07, 0.112, and 0.07, respectively). IGF2BP2 expression levels also showed variations based on gender, age, genetic abnormality, and disease subtype, but without statistical significance. In conclusion, expression of IGF2BP2 showed up-regulated levels in AML, particularly in patients positive for the immunophenotypic markers CD4, CD11b, CD35, CD36, cTdT, and IREM2. IGF2BP2 expression may be affected by gender, age, genetic abnormalities, and AML subtypes.</div></div>","PeriodicalId":12673,"journal":{"name":"Gene Reports","volume":"41 ","pages":"Article 102331"},"PeriodicalIF":0.9000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gene Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452014425002043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

IGF2BP2 (insulin-like growth factor 2 mRNA-binding protein 2) is a gene that encodes a protein (IGF2BP2) involved in promoting RNA stability, facilitating RNA translation, and regulating post-transcriptional processes. Recent evidence indicates that IGF2BP2 is overexpressed in acute myeloid leukemia (AML). However, the association between IGF2BP2 expression and genetic abnormalities in AML remains poorly understood. Furthermore, IGF2BP2 expression across AML subtypes and immunophenotypes has yet to be characterized. In this retrospective study, IGF2BP2 mRNA expression was evaluated in 106 AML patients, with a focus on understanding the relationship between IGF2BP2 expression and disease subtype, genetic abnormalities, and peripheral blood immunophenotypes. IGF2BP2 expression (relative fold change; 2^−ΔΔCt) in peripheral blood was determined using quantitative PCR analysis. Results revealed that IGF2BP2 was overexpressed in AML patients (median: 1.20; interquartile range 25–75 %: 0.73–2.39; range: 0.51–4.25). IGF2BP2 overexpression was more pronounced in cases positive for cluster of differentiation (CD) 4, CD11b, CD35, CD36, cTdT (cytoplasmic terminal deoxynucleotidyl transferase), and IREM2 (immune receptor expressed by myeloid cells 2) than in cases negative for the corresponding markers, but the adjusted probability for multiple comparisons was not statistically significant (0.14, 0.07, 0.21, 0.07, 0.112, and 0.07, respectively). IGF2BP2 expression levels also showed variations based on gender, age, genetic abnormality, and disease subtype, but without statistical significance. In conclusion, expression of IGF2BP2 showed up-regulated levels in AML, particularly in patients positive for the immunophenotypic markers CD4, CD11b, CD35, CD36, cTdT, and IREM2. IGF2BP2 expression may be affected by gender, age, genetic abnormalities, and AML subtypes.

查看原文本刊更多论文

IGF2BP2基因在急性髓性白血病患者中表现出免疫表型依赖性过表达

IGF2BP2（胰岛素样生长因子2 mrna结合蛋白2）是一种编码蛋白（IGF2BP2）的基因，参与促进RNA稳定性、促进RNA翻译和调节转录后过程。最近的证据表明，IGF2BP2在急性髓性白血病（AML）中过表达。然而，IGF2BP2表达与AML遗传异常之间的关系仍然知之甚少。此外，IGF2BP2在AML亚型和免疫表型中的表达尚未被表征。在这项回顾性研究中，我们评估了106例AML患者的IGF2BP2 mRNA表达，重点了解IGF2BP2表达与疾病亚型、遗传异常和外周血免疫表型之间的关系。采用定量PCR检测外周血IGF2BP2的表达（相对折叠变化；2−ΔΔCt）。结果显示，IGF2BP2在AML患者中过表达（中位数：1.20；四分位数范围25 - 75%；0.73-2.39；范围：0.51-4.25）。IGF2BP2在cd4、CD11b、CD35、CD36、cTdT（细胞质末端脱氧核苷酸转移酶）和IREM2（骨髓细胞表达的免疫受体2）标记阳性的患者中过表达明显高于相应标记阴性的患者，但多次比较调整后的概率无统计学意义（分别为0.14、0.07、0.21、0.07、0.112、0.07）。IGF2BP2表达水平在性别、年龄、基因异常、疾病亚型等方面也存在差异，但无统计学意义。总之，IGF2BP2在AML中表达水平上调，特别是在免疫表型标记物CD4、CD11b、CD35、CD36、cTdT和IREM2阳性的患者中。IGF2BP2的表达可能受性别、年龄、遗传异常和AML亚型的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gene Reports Biochemistry, Genetics and Molecular Biology-Genetics

CiteScore

3.30

自引率

7.70%

发文量

246

审稿时长

49 days

期刊介绍： Gene Reports publishes papers that focus on the regulation, expression, function and evolution of genes in all biological contexts, including all prokaryotic and eukaryotic organisms, as well as viruses. Gene Reports strives to be a very diverse journal and topics in all fields will be considered for publication. Although not limited to the following, some general topics include: DNA Organization, Replication & Evolution -Focus on genomic DNA (chromosomal organization, comparative genomics, DNA replication, DNA repair, mobile DNA, mitochondrial DNA, chloroplast DNA). Expression & Function - Focus on functional RNAs (microRNAs, tRNAs, rRNAs, mRNA splicing, alternative polyadenylation) Regulation - Focus on processes that mediate gene-read out (epigenetics, chromatin, histone code, transcription, translation, protein degradation). Cell Signaling - Focus on mechanisms that control information flow into the nucleus to control gene expression (kinase and phosphatase pathways controlled by extra-cellular ligands, Wnt, Notch, TGFbeta/BMPs, FGFs, IGFs etc.) Profiling of gene expression and genetic variation - Focus on high throughput approaches (e.g., DeepSeq, ChIP-Seq, Affymetrix microarrays, proteomics) that define gene regulatory circuitry, molecular pathways and protein/protein networks. Genetics - Focus on development in model organisms (e.g., mouse, frog, fruit fly, worm), human genetic variation, population genetics, as well as agricultural and veterinary genetics. Molecular Pathology & Regenerative Medicine - Focus on the deregulation of molecular processes in human diseases and mechanisms supporting regeneration of tissues through pluripotent or multipotent stem cells.